CD38 and neoplasm: Additionally, isatuximab inhibits the ADP-ribosyl cyclase activity of CD38, likely through allosteric antagonism, activates natural killer (NK) cells even in the absence of CD38+ tumor cells, and suppresses CD38+ regulatory T cells [47].